Oncopeptalks on the recent FDA decision

In this episode of Oncopeptalks, Jakob Lindberg, Chief Scientific Officer discusses the recent decision by the U.S. Food and Drug Administration to reconfirm the withdrawal of Pepaxto in a conversation with David Augustsson, Head of IR and Communication. Topics covered are the journey from U.S. approval to withdrawal for Pepaxto, his view on the recent decision and next, if any, steps in the USA for the drug.

Watch the video below. (Also available in Swedish, with similar content)

If you have any questions or issues that you’d like to have addressed in future editions, reach out to David at david.augustsson@oncopeptides.com